Replies to post #145 on Artelo Biosciences Inc (ARTL)

[tw0122]

1.79 dip

[georgie18]

ARTL...$2.03...🥳...Hit $3.10 this morning...

georgie18

Member Level
Re: georgie18 post# 140

Tuesday, December 02, 2025 12:29:16 PM

Post#
145
of 149
ARTL...$1.93...🥳...Zero Borrow...Back in here on the $1.60 Range dip...

georgie18

Member Level
Re: georgie18 post# 698501

Monday, September 22, 2025 10:03:03 AM

Post#
699501
of 707708
ARTL...$6.02...Hod...🥳...$4.90s/$5.30s Looking better here...

georgie18

Member Level
Re: georgie18 post# 138

Monday, September 15, 2025 11:28:38 AM

Post#
139
of 139
ARTL...Added the $4.90 Dip...🥳

georgie18

Member Level
Re: None

Friday, September 12, 2025 8:45:53 PM

Post#
698332
of 698498
ARTL...$5.31...🥳... https://schrts.co/AUmYdsGy ...Oversold Chart with Open Gap in the $8 range...Dip caused by 3 million offering on Sept 5... Float under 3 Million...

SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9 million.

The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.